Physician profile
Chau Hoang
NPI 1245523737
$2,883.31
in general payments reported to CMS, 2019-2025
9 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $197 · 2021: $176 · 2022: $528 · 2023: $793 · 2024: $365 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661 · Education: $28.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.67 |
| Education | $28.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $837.68 | 2020-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $813.99 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $423.97 | 2022-2025 | |
| Amarin Pharma, INC. | $305.63 | 2019-2023 | |
| Abbott Laboratories | $241.49 | 2022-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $147.57 | 2020-2022 | |
| Amgen INC. | $52.43 | 2023-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $41.55 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $19.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chau Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.